Biogen

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Investors Business Daily
Ionis Pharmaceuticals
Biogen
ALS
FDA
tofersen
Flag link:
FDA advisers support conditional clearance of Biogen’s ALS drug
FDA advisers support conditional clearance of Biogen’s ALS drug
BioPharma Dive
Biogen
ALS
FDA
tofersen
Flag link:
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
BioSpace
ALS
Biogen
Ionis Pharmaceuticals
FDA
tofersen
clinical trials
Flag link:
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
BioSpace
Sangamo Therapeutics
Novartis
Biogen
neurology
gene regulation therapies
Flag link:
Alzheimer's Association campaigns for broader Leqembi coverage: report
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Biogen's head of neurodegeneration leaves
Biogen's head of neurodegeneration leaves
Fierce Biotech
Biogen
women executives
Aduhelm
Alzheimer's disease
Flag link:
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Seeking Alpha
Biogen
EMA
Europe
MS
multiple sclerosis
Tecfidera
generics
Flag link:
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Flag link:
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Eisai
Biogen
Alzheimer's disease
Leqembi
Flag link:
Biogen names Stelios Papadopoulos' successor
Biogen names Stelios Papadopoulos' successor
Fierce Biotech
Biogen
Stelios Papadopoulos
Caroline Dorsa
Flag link:
FDA says no adcomm planned for Biogen, Sage's depression drug
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Biogen
SAGE Therapeutics
FDA
zuranolone
major depressive disorder
postpartum depression
Flag link:
FDA sets July decision date for full approval of Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
Flag link:
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
Billy Dunn, FDA’s top neuroscience official to depart agency
Billy Dunn, FDA’s top neuroscience official to depart agency
RAPS.org
Billy Dunn
FDA
Neurosciences
Biogen
Aduhelm
Flag link:
Medicare maintains limits on Eisai’s new Alzheimer’s drug
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue
Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue
Endpoints
Biogen
InnoCare Pharma
orelabrutinib
earnings
Flag link:
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Fierce Pharma
Biogen
Chris Viehbacher
Stelios Papadopoulos
Pharma CEOs
Alzheimer's disease
Leqembi
Flag link:
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
Endpoints
Biogen
Aduhelm
FDA
Alzheimer's disease
Flag link:
Biogen, Sage Get FDA Priority Review of Zuranolone
Biogen, Sage Get FDA Priority Review of Zuranolone
Marketwatch
Biogen
SAGE Therapeutics
FDA
zuranolone
priority review
postpartum depression
major depressive disorder
Flag link:

Pages